查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
器官移植排斥反應藥物市場 - 2022-2031年全球行業分析、規模、佔有率、成長、趨勢和預測
市場調查報告書
商品編碼
1301470

器官移植排斥反應藥物市場 - 2022-2031年全球行業分析、規模、佔有率、成長、趨勢和預測

Organ Transplant Rejection Medication Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 241 Pages | 商品交期: 2-10個工作天內

價格

器官移植排斥反應藥物市場- 報告範圍

TMR關於全球器官移植排斥反應藥物市場的報告研究了過去以及當前的成長趨勢和機會，以獲得對2023年至2031年預測期間的市場指標的寶貴見解。報告提供了2017-2031年期間全球器官移植排斥反應藥物市場的收入，考慮到2023年為基準年，2031年為預測年。報告還提供了2023年至2031年全球器官移植排斥藥物治療市場的複合年成長率（CAGR %）。

該報告是在廣泛的研究後編寫的。一級研究涉及大部分的研究工作，其中分析師與關鍵意見領袖、行業領袖和意見製造者進行了訪談。二級研究包括參考主要參與者的產品資料、年度報告、新聞稿和相關文件，以了解器官移植排斥反應藥物的市場。

報告深入研究了全球器官移植排斥反應藥物市場的競爭格局。已經確定了在全球器官移植排異反應藥物治療市場運作的主要參與者，並對其中每一個參與者的各種屬性進行了分析。公司概況、財務狀況、最近的發展和SWOT是本報告中對全球器官移植排斥藥物治療市場參與者的屬性描述。

目錄

第一章：前言

  • 市場定義和範圍
  • 市場細分
  • 主要研究目標
  • 研究重點

第二章：假設和研究方法

第三章：執行摘要：全球市場

第四章：市場概述

  • 簡介
    • 細分市場的定義
  • 概述
  • 市場動態
    • 驅動力
    • 限制因素
    • 機會
  • 2017-2031年全球市場分析與預測

第五章：關鍵洞察力

  • 當前的全球情況：移植用器官捐獻
  • 主要產品/品牌分析
  • 管線分析
  • COVID-19影響分析

第六章：全球市場分析與預測：按藥物類別分類

  • 介紹和定義
  • 主要研究結果/發展情況
  • 市場價值預測：按藥物類別，2017-2031年
    • 抗體
      • 胸腺球蛋白
      • Alemtuzumab
      • 貝拉塔普
      • 穆羅單抗-CD3
      • 巴西利希單抗
      • 艾庫利珠單抗
    • 抗代謝藥物
      • 硫唑嘌呤
      • 黴酚酸酯（Mycophenolate Mofetil
      • 黴酚酸鈉，MPA
    • 鈣素酶抑製劑
      • 環孢素
      • 他克莫司
    • mTOR抑製劑
      • 西羅莫司
      • 埃沃利姆斯
    • 類固醇
      • 潑尼松龍
      • 甲基潑尼松龍
  • 市場吸引力分析：按藥物類別

第七章：全球市場分析與預測：按移植類型分類

  • 介紹和定義
  • 主要研究結果/發展
  • 市場價值預測：按移植類型，2017-2031年
    • 腎臟
    • 肝臟
    • 心臟
    • 肺臟
    • 胰腺
    • 其他類型
  • 市場吸引力分析：按移植類型

第八章：全球市場分析與預測：按配銷通路分類

  • 介紹和定義
  • 主要研究結果/發展
  • 市場價值預測：按配銷通路分類，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場吸引力分析：按配銷通路分類

第九章：全球市場分析與預測：按地區分類

  • 主要發現
  • 市場價值預測：按地區分類，2017-2031年
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第十章：北美市場分析與預測

  • 簡介
    • 主要研究結果
  • 市場價值預測：按藥物類別，2017-2031年
    • 抗體
      • 胸腺球蛋白
      • 阿崙珠單抗
      • 貝拉塔普
      • 穆羅單抗-CD3
      • 巴西利希單抗
      • 艾庫利珠單抗
    • 抗代謝藥物
      • 硫唑嘌呤
      • 黴酚酸酯（Mycophenolate Mofetil
      • 黴酚酸鈉，MPA
    • 鈣素酶抑製劑
      • 環孢素
      • 他克莫司
    • mTOR抑製劑
      • 西羅莫司
      • 埃沃利姆斯
    • 類固醇
      • 潑尼松龍
      • 甲基潑尼松龍
  • 市場價值預測：按移植類型，2017-2031年
    • 腎臟
    • 肝臟
    • 心臟
    • 肺臟
    • 胰腺
    • 其他
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家分類，2017-2031年
    • 美國
    • 加拿大
  • 市場吸引力分析
    • 按藥物類別
    • 按移植類型分類
    • 按配銷通路分類
    • 按國家分類

第11章：歐洲市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按藥物類別，2017-2031年
    • 抗體
      • 胸腺球蛋白
      • 阿崙珠單抗
      • 貝拉塔普
      • 穆羅單抗-CD3
      • 巴西利希單抗
      • 艾庫利珠單抗
    • 抗代謝藥物
      • 硫唑嘌呤
      • 黴酚酸酯（Mycophenolate Mofetil
      • 黴酚酸鈉，MPA
    • 鈣素酶抑製劑
      • 環孢素
      • 他克莫司
    • mTOR抑製劑
      • 西羅莫司
      • 埃沃利姆斯
    • 類固醇
      • 潑尼松龍
      • 甲基潑尼松龍
  • 市場價值預測：按移植類型，2017-2031年
    • 腎臟
    • 肝臟
    • 心臟
    • 肺臟
    • 胰腺
    • 其他
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家/次區域分類，2017-2031年
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 市場吸引力分析
    • 按藥物類別
    • 按移植類型分類
    • 按配銷通路分類
    • 按國家/次區域分類

第十二章：亞太地區市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按藥物類別，2017-2031年
    • 抗體
      • 胸腺球蛋白
      • 阿崙珠單抗
      • 貝拉塔普
      • 穆羅單抗-CD3
      • 巴西利希單抗
      • 艾庫利珠單抗
    • 抗代謝藥物
      • 硫唑嘌呤
      • 黴酚酸酯（Mycophenolate Mofetil
      • 黴酚酸鈉，MPA
    • 鈣素酶抑製劑
      • 環孢素
      • 他克莫司
    • mTOR抑製劑
      • 西羅莫司
      • 埃沃利姆斯
    • 類固醇
      • 潑尼松龍
      • 甲基潑尼松龍
  • 市場價值預測：按移植類型，2017-2031年
    • 腎臟
    • 肝臟
    • 心臟
    • 肺臟
    • 胰腺
    • 其他
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家/次區域分類，2017-2031年
    • 中國
    • 日本
    • 印度
    • 澳大利亞和新西蘭
    • 亞太其他地區
  • 市場吸引力分析
    • 按藥物類別
    • 按移植類型
    • 按配銷通路
    • 按國家/次區域分類

第13章：拉丁美洲市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按藥物類別，2017-2031年
    • 抗體
      • 胸腺球蛋白
      • 阿崙珠單抗
      • 貝拉塔普
      • 穆羅單抗-CD3
      • 巴西利希單抗
      • 艾庫利珠單抗
    • 抗代謝藥物
      • 硫唑嘌呤
      • 黴酚酸酯（Mycophenolate Mofetil
      • 黴酚酸鈉，MPA
    • 鈣素酶抑製劑
      • 環孢素
      • 他克莫司
    • mTOR抑製劑
      • 西羅莫司
      • 埃沃利姆斯
    • 類固醇
      • 潑尼松龍
      • 甲基潑尼松龍
  • 市場價值預測：按移植類型，2017-2031年
    • 腎臟
    • 肝臟
    • 心臟
    • 肺臟
    • 胰腺
    • 其他
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家/次區域分類，2017-2031年
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 市場吸引力分析
    • 按藥物類別
    • 按移植類型分類
    • 按配銷通路分類
    • 按國家/次區域分類

第十四章：中東和非洲市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按藥物類別，2017-2031年
    • 抗體
      • 胸腺球蛋白
      • 阿崙珠單抗
      • 貝拉塔普
      • 穆羅單抗-CD3
      • 巴西利希單抗
      • 艾庫利珠單抗
    • 抗代謝藥物
      • 硫唑嘌呤
      • 黴酚酸酯（Mycophenolate Mofetil
      • 黴酚酸鈉，MPA
    • 鈣素酶抑製劑
      • 環孢素
      • 他克莫司
    • mTOR抑製劑
      • 西羅莫司
      • 埃沃利姆斯
    • 類固醇
      • 潑尼松龍
      • 甲基潑尼松龍
  • 市場價值預測：按移植類型，2017-2031年
    • 腎臟
    • 肝臟
    • 心臟
    • 肺臟
    • 胰腺
    • 其他
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家/次區域分類，2017-2031年
    • 海灣合作理事會國家
    • 南非
    • 中東和非洲其他地區
  • 市場吸引力分析
    • 按藥物類別
    • 按移植類型分類
    • 按配銷通路分類
    • 按國家/次區域分類

第十五章：競爭格局

  • 市場參與者- 競爭矩陣（按公司的層級和規模分類）
  • 市場佔有率分析：按公司分類(2022)
  • 公司簡介
    • Pfizer, Inc.
    • Astellas Pharma, Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Sanofi
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline plc
    • AbbVie, Inc.
    • Hansa Biopharma
    • WOCKHARDT
    • Viatris, Inc.
    • Glenmark
    • Biocon
    • Hikma Pharmaceuticals plc
    • Teva Pharmaceutical USA Inc.
    • Zydus Pharmaceuticals, Inc.
Product Code: TMRGL76123

Organ Transplant Rejection Medication Market - Scope of Report

TMR's report on the global Organ Transplant Rejection Medication market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Organ Transplant Rejection Medication market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Organ Transplant Rejection Medication market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Organ Transplant Rejection Medication market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Organ Transplant Rejection Medication market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Organ Transplant Rejection Medication market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Organ Transplant Rejection Medication market.

The report delves into the competitive landscape of the global Organ Transplant Rejection Medication market. Key players operating in the global Organ Transplant Rejection Medication market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Organ Transplant Rejection Medication market profiled in this report.

Key Questions Answered in Global Organ Transplant Rejection Medication Market Report:

  • What is the sales/revenue generated by Organ Transplant Rejection Medication across all regions during the forecast period?
  • What are the opportunities in the global Organ Transplant Rejection Medication market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Organ Transplant Rejection Medication Market - Research Objectives and Research Approach

The comprehensive report on the global Organ Transplant Rejection Medication market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Organ Transplant Rejection Medication market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Organ Transplant Rejection Medication market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Organ Transplant Rejection Medication Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Organ Transplant Rejection Medication Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Current Global Scenario: Organ Donation for Transplantation
  • 5.2. Key Product/Brand Analysis
  • 5.3. Pipeline Analysis
  • 5.4. COVID-19 Impact Analysis

6. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. Antibodies
      • 6.3.1.1. Thymoglobulin
      • 6.3.1.2. Alemtuzumab
      • 6.3.1.3. Belatacept
      • 6.3.1.4. Muromonab-CD3
      • 6.3.1.5. Basiliximab
      • 6.3.1.6. Eculizumab
    • 6.3.2. Antimetabolites
      • 6.3.2.1. Azathioprine
      • 6.3.2.2. Mycophenolate Mofetil
      • 6.3.2.3. Mycophenolate sodium, MPA
    • 6.3.3. Calcineurin Inhibitors
      • 6.3.3.1. Cyclosporine
      • 6.3.3.2. Tacrolimus
    • 6.3.4. mTOR Inhibitors
      • 6.3.4.1. Sirolimus
      • 6.3.4.2. Everolimus
    • 6.3.5. Steroids
      • 6.3.5.1. Prednisolone
      • 6.3.5.2. Methylprednisolone
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Transplant Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 7.3.1. Kidney
    • 7.3.2. Liver
    • 7.3.3. Heart
    • 7.3.4. Lung
    • 7.3.5. Pancreas
    • 7.3.6. Others
  • 7.4. Market Attractiveness Analysis, by Transplant Type

8. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Organ Transplant Rejection Medication Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. Antibodies
      • 10.2.1.1. Thymoglobulin
      • 10.2.1.2. Alemtuzumab
      • 10.2.1.3. Belatacept
      • 10.2.1.4. Muromonab-CD3
      • 10.2.1.5. Basiliximab
      • 10.2.1.6. Eculizumab
    • 10.2.2. Antimetabolites
      • 10.2.2.1. Azathioprine
      • 10.2.2.2. Mycophenolate Mofetil
      • 10.2.2.3. Mycophenolate sodium, MPA
    • 10.2.3. Calcineurin Inhibitors
      • 10.2.3.1. Cyclosporine
      • 10.2.3.2. Tacrolimus
    • 10.2.4. mTOR Inhibitors
      • 10.2.4.1. Sirolimus
      • 10.2.4.2. Everolimus
    • 10.2.5. Steroids
      • 10.2.5.1. Prednisolone
      • 10.2.5.2. Methylprednisolone
  • 10.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 10.3.1. Kidney
    • 10.3.2. Liver
    • 10.3.3. Heart
    • 10.3.4. Lung
    • 10.3.5. Pancreas
    • 10.3.6. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Transplant Type
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Organ Transplant Rejection Medication Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. Antibodies
      • 11.2.1.1. Thymoglobulin
      • 11.2.1.2. Alemtuzumab
      • 11.2.1.3. Belatacept
      • 11.2.1.4. Muromonab-CD3
      • 11.2.1.5. Basiliximab
      • 11.2.1.6. Eculizumab
    • 11.2.2. Antimetabolites
      • 11.2.2.1. Azathioprine
      • 11.2.2.2. Mycophenolate Mofetil
      • 11.2.2.3. Mycophenolate sodium, MPA
    • 11.2.3. Calcineurin Inhibitors
      • 11.2.3.1. Cyclosporine
      • 11.2.3.2. Tacrolimus
    • 11.2.4. mTOR Inhibitors
      • 11.2.4.1. Sirolimus
      • 11.2.4.2. Everolimus
    • 11.2.5. Steroids
      • 11.2.5.1. Prednisolone
      • 11.2.5.2. Methylprednisolone
  • 11.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 11.3.1. Kidney
    • 11.3.2. Liver
    • 11.3.3. Heart
    • 11.3.4. Lung
    • 11.3.5. Pancreas
    • 11.3.6. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Transplant Type
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Organ Transplant Rejection Medication Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. Antibodies
      • 12.2.1.1. Thymoglobulin
      • 12.2.1.2. Alemtuzumab
      • 12.2.1.3. Belatacept
      • 12.2.1.4. Muromonab-CD3
      • 12.2.1.5. Basiliximab
      • 12.2.1.6. Eculizumab
    • 12.2.2. Antimetabolites
      • 12.2.2.1. Azathioprine
      • 12.2.2.2. Mycophenolate Mofetil
      • 12.2.2.3. Mycophenolate sodium, MPA
    • 12.2.3. Calcineurin Inhibitors
      • 12.2.3.1. Cyclosporine
      • 12.2.3.2. Tacrolimus
    • 12.2.4. mTOR Inhibitors
      • 12.2.4.1. Sirolimus
      • 12.2.4.2. Everolimus
    • 12.2.5. Steroids
      • 12.2.5.1. Prednisolone
      • 12.2.5.2. Methylprednisolone
  • 12.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 12.3.1. Kidney
    • 12.3.2. Liver
    • 12.3.3. Heart
    • 12.3.4. Lung
    • 12.3.5. Pancreas
    • 12.3.6. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Transplant Type
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Organ Transplant Rejection Medication Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. Antibodies
      • 13.2.1.1. Thymoglobulin
      • 13.2.1.2. Alemtuzumab
      • 13.2.1.3. Belatacept
      • 13.2.1.4. Muromonab-CD3
      • 13.2.1.5. Basiliximab
      • 13.2.1.6. Eculizumab
    • 13.2.2. Antimetabolites
      • 13.2.2.1. Azathioprine
      • 13.2.2.2. Mycophenolate Mofetil
      • 13.2.2.3. Mycophenolate sodium, MPA
    • 13.2.3. Calcineurin Inhibitors
      • 13.2.3.1. Cyclosporine
      • 13.2.3.2. Tacrolimus
    • 13.2.4. mTOR Inhibitors
      • 13.2.4.1. Sirolimus
      • 13.2.4.2. Everolimus
    • 13.2.5. Steroids
      • 13.2.5.1. Prednisolone
      • 13.2.5.2. Methylprednisolone
  • 13.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 13.3.1. Kidney
    • 13.3.2. Liver
    • 13.3.3. Heart
    • 13.3.4. Lung
    • 13.3.5. Pancreas
    • 13.3.6. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Transplant Type
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Organ Transplant Rejection Medication Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. Antibodies
      • 14.2.1.1. Thymoglobulin
      • 14.2.1.2. Alemtuzumab
      • 14.2.1.3. Belatacept
      • 14.2.1.4. Muromonab-CD3
      • 14.2.1.5. Basiliximab
      • 14.2.1.6. Eculizumab
    • 14.2.2. Antimetabolites
      • 14.2.2.1. Azathioprine
      • 14.2.2.2. Mycophenolate Mofetil
      • 14.2.2.3. Mycophenolate sodium, MPA
    • 14.2.3. Calcineurin Inhibitors
      • 14.2.3.1. Cyclosporine
      • 14.2.3.2. Tacrolimus
    • 14.2.4. mTOR Inhibitors
      • 14.2.4.1. Sirolimus
      • 14.2.4.2. Everolimus
    • 14.2.5. Steroids
      • 14.2.5.1. Prednisolone
      • 14.2.5.2. Methylprednisolone
  • 14.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 14.3.1. Kidney
    • 14.3.2. Liver
    • 14.3.3. Heart
    • 14.3.4. Lung
    • 14.3.5. Pancreas
    • 14.3.6. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Transplant Type
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Pfizer, Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Astellas Pharma, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Novartis AG
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. F. Hoffmann-La Roche Ltd.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Sanofi
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Bristol-Myers Squibb Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. GlaxoSmithKline plc
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. AbbVie, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. Hansa Biopharma
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. WOCKHARDT
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Business Strategies
      • 15.3.10.4. Recent Developments
    • 15.3.11. Viatris, Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Financial Overview
      • 15.3.11.3. Product Portfolio
      • 15.3.11.4. Business Strategies
      • 15.3.11.5. Recent Developments
    • 15.3.12. Glenmark
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Financial Overview
      • 15.3.12.3. Product Portfolio
      • 15.3.12.4. Business Strategies
      • 15.3.12.5. Recent Developments
    • 15.3.13. Biocon
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Financial Overview
      • 15.3.13.3. Product Portfolio
      • 15.3.13.4. Business Strategies
      • 15.3.13.5. Recent Developments
    • 15.3.14. Hikma Pharmaceuticals plc
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Financial Overview
      • 15.3.14.3. Product Portfolio
      • 15.3.14.4. Business Strategies
      • 15.3.14.5. Recent Developments
    • 15.3.15. Teva Pharmaceutical U.S.A Inc.
      • 15.3.15.1. Company Overview
      • 15.3.15.2. Financial Overview
      • 15.3.15.3. Product Portfolio
      • 15.3.15.4. Business Strategies
      • 15.3.15.5. Recent Developments
    • 15.3.16. Zydus Pharmaceuticals, Inc.
      • 15.3.16.1. Company Overview
      • 15.3.16.2. Financial Overview
      • 15.3.16.3. Product Portfolio
      • 15.3.16.4. Business Strategies
      • 15.3.16.5. Recent Developments

List of Tables

  • Table 01: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 03: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 04: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 05: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 06: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 07: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 08: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 10: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 12: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 13: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 14: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 15: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 16: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 17: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 19: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 20: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 21: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 22: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 23: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 24: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 25: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 26: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 27: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 28: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 29: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 30: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 31: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 32: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 33: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 34: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 35: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 36: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 37: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 38: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 39: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 40: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 41: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 42: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 43: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 44: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 45: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 46: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 47: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 48: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 49: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 50: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 51: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 52: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 53: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 54: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Organ Transplant Rejection Medications Market Value Share, by Drug Class, 2022
  • Figure 03: Global Organ Transplant Rejection Medications Market Value Share, by Transplant Type, 2022
  • Figure 04: Global Organ Transplant Rejection Medications Market Value Share, by Distribution Channel, 2022
  • Figure 05: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 06: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 07: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Antibodies, 2017-2031
  • Figure 08: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Antimetabolites, 2017-2031
  • Figure 09: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Calcineurin Inhibitors, 2017-2031
  • Figure 10: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by mTOR Inhibitors, 2017-2031
  • Figure 11: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Steroids, 2017-2031
  • Figure 12: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 13: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 14: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Kidney, 2017-2031
  • Figure 15: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Liver, 2017-2031
  • Figure 16: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Heart, 2017-2031
  • Figure 17: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Lung, 2017-2031
  • Figure 18: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Pancreas, 2017-2031
  • Figure 19: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 20: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 21: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 22: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 23: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 24: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 25: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 26: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 27: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 28: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 29: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 30: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 31: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 32: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 34: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 35: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 36: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 38: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 39: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 40: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 41: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 42: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 43: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 44: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 45: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 46: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 47: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 48: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 49: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 50: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 51: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 52: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 53: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 54: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 55: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 56: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 57: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 58: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 59: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 60: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 61: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 62: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 63: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 64: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 65: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 66: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 67: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 68: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 69: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 70: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 71: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031